Imperial Oil Limited Common Stock vs Novavax Inc — how do they compare? Imperial Oil Limited Common Stock trades at $130.2 (market cap $62.22B), while Novavax Inc trades at $12.44 (market cap $2.11B). The key difference: Imperial Oil Limited Common Stock is far larger — about 29.5× Novavax Inc's market cap, and Imperial Oil Limited Common Stock pays a 1.9% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| IMO | NVAX | |
|---|---|---|
Market Cap | $62.22B | $2.11B |
Volume | 560,544 | 8,376,831 |
Sector | Energy | Health |
52-Week High | $138.33 | $12.82 |
52-Week Low | $83.72 | $6.22 |
Enterprise Value | $63.13B | $1.69B |
Dividend Yield | 1.9% | — |
Typical Hold Time | — | 59 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.82, up 1.26% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and strategic pivots toward its Matrix-M adjuvant platform and partnerships, such as with Sanofi for COVID-19 vaccines, highlight operational progress. However, negative cash flows and a net loss in 2026 projections underscore financial volatility amid transitioning revenue streams.
The outlook balances near-term catalysts from vaccine approvals and partnership momentum against persistent cash burn and competitive pressures. Investors face opportunity in undervalued metrics like a low P/E of 3.14, but risks include execution hurdles and dependency on successful licensing deals to achieve sustainable profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →